An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458;anti-BCMA x anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients with Relapsed/Refractory Multiple Myeloma (LINKER-